EWING, N.J. (AP) — Antares Pharma Inc. said Thursday the Food and Drug Administration has approved its topical gel for the treatment of overactive bladder.
The Ewing, N.J., company said the clear, odorless oxybutynin gel will be available in a metered pump. It will launch the product with Watson Pharmaceuticals Inc., which will sell it in the United States and Canada.
Watson will make milestone payments based on sales levels and will be responsible for some manufacturing startup activities, the companies said in July, when they announced their agreement.
Antares said overactive bladders affect more than 33 million Americans. The condition is characterized by a sudden, uncomfortable need to urinate and may include incontinence.
Antares shares fell nearly 3 percent, or 8 cents, to $2.70 in morning trading, and Watson shares fell 17 cents to $61.81. Meanwhile, broader trading indexes were down less than 1 percent.
- Food and Drug Administration
- overactive bladder